Bristol-myers Squibb Compnay

Mario Maldonado

William N Washburn

Paul Strumph

James F List

Frederick T Fiedorek

Jean Whaley

Methods are provided for treating cancers that have high glucose requirements and that express SGLT2 at levels higher than normal cells, such as metastatic cancers, for example, metastatic lung cancers, employing an SGLT2 inhibitor alone or in combination with a cytotoxic agent and to a composition containing a combination of an SGLT2 inhibitor and a cytotoxic agent.

Method for treating cancers having high glucose requirements employing an SGLT2 inhibitor and compositions thereof

Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which comprises an SGLT2 inhibitor, alone or in combination with another anti-obesity agent, and a pharmaceutically acceptable carrier thereof.

Growing community of inventors

Basel, Switzerland

Mario Maldonado